Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients ...Leggi tutto